Olema Oncology: ENA 2022: OP-1250 Phase 1/2 Study Update
About The Event
Olema invites you to join us for a virtual webcast and conference call with Sean P. Bohen, M.D., Ph.D., (President & CEO, Olema), Shane Kovacs (COO and CFO, Olema), and Naseem Zojwalla, M.D. (CMO, Olema) to review data presented in a poster at the 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics. The poster title is “Preliminary phase 1/2 results from OP-1250-001, a study of OP-1250, an oral CERAN/SERD, in subjects with advanced and/or metastatic estrogen receptor (ER)-positive, HER2-negative breast cancer (NCT04505826).”
Lead study author, Dr. Erika Hamilton, Director of Breast Cancer and Gynecologic Cancer Research for Sarah Cannon Research Institute at Tennessee Oncology, will join Olema management for the call.
A live Q&A will follow the formal presentations.